Generic Drug Regulations India Online

The Delhi High Court dispute
More recently, a petition has been filed by Bayer, a multinational pharmaceutical company, in which they have requested the court to ask DCGI and the Controller General of Patents to work collectively for the regulation of drugs. The dispute was raised when DCGI authorized Cipla, another big pharma of India, to market their anti-cancer drug which was similar to the Bayer’s. Bayer’s requested the court that such an authorization will encourage duplicity of drugs and would lower their market value significantly. The court made a decision in favor of Bayer and announced a statement according to which no drug can be granted a marketing authorization if its counter part, similar drug is already patented. The order was strongly criticized by pharmaceuticals as it disabled the process of patenting generic drugs before the patent of brand-name drug expires.